hospit
prato
itali
phone
fax
mobil
email
fbrzcantini
gmailcom
discuss
journal
recent
new
use
angiotensin
convert
receptor
enter
airway
cell
viral
endocytosi
mediat
sever
factor
includ
clathrin
adaptor
complex
adaptorassoci
accord
recent
report
diseas
caus
character
three
clinic
pattern
symptom
mild
moder
diseas
sever
pneumonia
requir
admiss
intens
care
unit
icu
patient
thu
far
specif
therapi
infect
benefit
lopinavirritonavir
treatment
result
recent
trial
hydroxychloroquin
current
use
view
vitro
observ
effect
reduct
viral
replic
seem
unsatisfactori
elev
proinflammatori
cytokinechemokin
respons
seem
associ
respiratori
failur
recent
tocilizumab
inhibitor
report
effect
patient
sever
pneumonia
baricitinib
anoth
inhibitor
cytokinereleas
seem
interest
antiinflammatori
drug
janu
kinas
inhibitor
antijak
licens
treatment
rheumatoid
arthriti
ra
good
efficaci
safeti
record
moreov
seem
antivir
effect
affin
protein
reduc
endocytosi
basi
assess
safeti
baricitinib
therapi
combin
lopinavirritonavir
moder
pneumonia
patient
evalu
clinic
impact
consecut
hospit
patient
march
th
th
moder
pneumonia
older
year
treat
week
baricitinib
tablet
mgday
ad
ritonavirlopinavir
therapi
last
consecut
patient
moder
pneumonia
receiv
standard
care
therapi
lopinavirritonavir
tablet
mgbid
hydroxychloroquin
mgdayor
week
admit
date
first
baricitinibtr
patient
serv
control
antibiot
schedul
case
suspect
bacteri
infect
inclus
criteria
posit
nasalor
swab
b
presenc
least
follow
symptom
fever
cough
myalgia
fatigu
c
evid
radiolog
pneumonia
discharg
patient
treat
baricitinib
plan
follow
addit
week
exclus
criteria
histori
thrombophleb
tp
latent
tuberculosi
infect
quantiferon
plustest
posit
qiagen
germani
pregnanc
lactat
mild
moder
diseas
definit
presenc
bilater
pneumonia
without
ground
glass
opac
absenc
consolid
requir
intub
enrol
arteri
oxygen
satur
roomair
ratio
arteri
oxygen
partial
pressurefract
inspir
oxygen
mmhg
paramet
daili
access
fever
pulmonari
function
modifi
earli
warn
score
mew
puls
rate
blood
pressur
initi
execut
radiolog
imag
perform
demand
laboratori
investig
includ
blood
cell
count
differenti
count
test
liver
kidney
function
erythrocyt
sediment
rate
esr
creactiv
protein
crp
procalcitonin
trial
approv
aziendausl
toscana
centro
committe
offlabel
use
drug
patient
sign
written
inform
consent
particip
studi
descript
statist
present
median
interquartil
rang
iqr
calcul
use
comorbid
similar
two
group
baricitinibtreat
well
toler
seriou
advers
event
ae
therapi
withdrawn
patient
day
treatment
due
consist
transaminas
elev
ast
ul
alt
ul
probabl
due
antivir
therapi
rather
baricitinib
treatment
mainli
renalmetabol
addit
bacteri
opportunist
infect
trombofleb
hematolog
toxic
observ
result
summar
tabl
overal
baricitinibtr
group
clinic
characterist
respiratori
function
paramet
significantli
improv
week
week
compar
baselin
crp
valu
significantli
decreas
timefram
controlgroup
signific
chang
record
week
compar
baselin
fever
crp
mew
significantli
improv
baricitinibtr
group
compar
control
p
respect
icu
transfer
request
control
none
baricitinibtr
patient
discharg
week
occur
baricitinibtr
patient
vs
control
discharg
neg
viral
nasalor
swab
preliminari
result
patient
moder
pneumonia
confirm
safeti
baricitinib
therapi
clinic
context
differ
ra
infect
cardiovascular
hematolog
ae
occur
week
treatment
shortterm
drug
exposur
may
probabl
explain
absenc
suppos
ae
confirm
longterm
safeti
patient
followedup
week
restrict
time
treatment
short
halflif
drug
hour
suggest
unlik
later
ae
occurr
remark
week
week
baricitinib
therapi
significantli
improv
clinic
laboratori
paramet
none
patient
requir
icu
support
major
patient
discharg
result
like
due
rapid
action
drug
short
median
interv
day
symptomsonset
therapi
start
major
limit
pilot
studi
openlabel
design
random
low
number
treat
patient
proper
control
group
miss
inde
requir
formal
demonstr
efficaci
therapi
use
baritinicib
therapi
may
limit
cytokinereleas
syndrom
associ
may
use
act
widerang
cytokin
although
result
gener
patient
believ
data
encourag
term
safeti
improv
clinic
impact
reduct
sever
progress
may
firststep
futur
control
larger
studi
work
partli
support
italian
ministri
health
ricerca
corrent
linea
laboratori
respiratori
paramet
patient
week
treatment
baricitinibtr
group
standardtr
group
comparison
within
treatment
group
differ
treatment
group
baricitinib
